Anand Desai, managing director of Anupam Rasayan, said, "This is a natural extension of our company's capabilities built over a decade in flow chemistry to manufacture niche pharma intermediates for various key customers on custom manufacturing model. The MoU perfectly aligns with our strategic objective of increasing the target market for our chemistries and expanding our pharma portfolio in an accelerated manner by enhancing the product basket offerings. It serves as yet another testament to our long-term revenue visibility and sustainable business model."

N.Govindarajan, CEO of 3xper Innoventure, said, “3xper is delighted to forge this collaboration to leverage each other's capabilities and create value. We are a young and nimble organisation and forging this kind of collaboration will help 3xper to enhance its playing field and reach to global customers. This collaboration fits into our strategic imperatives to fulfil our aspirations to become the global CDMO with differentiated technology platforms to leverage and foster innovation for the customers."

Anupam Rasayan India is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Its business verticals are life science related specialty chemicals comprising products related to agrochemicals, personal care and pharmaceuticals, and other specialty chemicals, comprising specialty pigment and dyes, and polymer additives.

The company's consolidated net profit increased 22.93% to Rs 56.67 crore on 47.71% jump in revenue from operations to Rs 479.96 crore in Q4 FY23 over Q4 FY22.

The scrip was down 0.66% to Rs 997.45 on the BSE.